Company Overview of Phibro Animal Health Corporation
Phibro Animal Health Corporation operates as a diversified developer, manufacturer, and marketer of a range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy, and aquaculture. It also sells specialty ingredients for use in the personal care, automotive, industrial chemical, and chemical catalyst industries. The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The Animal Health segment offers antibacterials, anticoccidials, and vaccines, which help prevent and manage infectious diseases in livestock and enhance food safety; and nutritional specialty products, which aid the continued he...
300 Frank West Burr Boulevard
Glenpointe Centre East
Teaneck, NJ 07666
Key Executives for Phibro Animal Health Corporation
Chairman, Chief Executive Officer, President, Member of Compensation Committee and Member of Retirement Benefits Committee
Total Annual Compensation: $3.0M
Chief Operating Officer and Director
Total Annual Compensation: $914.7K
President of Animal Health
Total Annual Compensation: $708.5K
Compensation as of Fiscal Year 2014.
Phibro Animal Health Corporation Key Developments
Phibro Animal Health Corporation Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015; Provides Earnings Guidance for the Year Ending June 30, 2015
May 11 15
Phibro Animal Health Corporation announced consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, the company reported net sales of $187.5 million against $173.3 million a year ago. Operating income was $21.8 million against $17.3 million a year ago. Income before income taxes was $22.8 million against $8.3 million a year ago. Net income was $19.4 million against $6.4 million a year ago. Diluted net income per share was $0.49 against $0.21 a year ago. Adjusted EBITDA was $27.5 million against $22.4 million a year ago. EBITDA was $31.8 million against $22.2 million a year ago. Adjusted net income was $16.5 million against $14.0 million a year ago. Adjusted diluted net income per share was $0.41 against $0.36 a year ago. Adjusted operating income was $23.4 million against $18.5 million a year ago. Adjusted income before income taxes was $20.0 million against $15.1 million a year ago. Net cash provided by operating activities was $21.1 million against $0.2 million a year ago. Capital expenditures were $5.4 million against $4.5 million a year ago.
For the year, the company reported net sales of $563.6 million against $508.2 million a year ago. Operating income was $66.7 million against $50.7 million a year ago. Income before income taxes was $63.0 million against $22.5 million a year ago. Net income was $55.3 million against $14.5 million a year ago. Diluted net income per share was $1.39 against $0.48 a year ago. Adjusted EBITDA was $83.0 million against $66.4 million a year ago. EBITDA was $89.5 million against $64.3 million a year ago. Adjusted net income was $50.9 million against $39.4 million a year ago. Adjusted diluted net income per share was $1.28 against $1.00 a year ago. Adjusted operating income was $70.4 million against $54.5 million a year ago. Adjusted income before provision for income taxes was $60.0 million against $44.3 million a year ago. Net cash provided by operating activities was $46.8 million against $16.6 million a year ago. Capital expenditures were $13.1 million against $14.2 million a year ago.
For the year ending June 30, 2015, the company expects net sales will be approximately $749 to $754 million, an increase of 8% to 9%. This reflects a slowing of Animal Health rate of growth as some of Animal Health ex-U.S. customers have delayed or reduced purchases due to the strong U.S. dollar. The company expects Mineral Nutrition net sales for the balance of the year to be approximately even with last year, due to the overlap with strong net sales last year. Adjusted EBITDA will be approximately $109 to $110 million, an increase of 20% to 21%. Adjusted diluted EPS will be approximately $1.65 to $1.67 per share, compared with $1.22 last year. The company anticipates increased CapEx investment going forward for the remainder of current fiscal year and into next fiscal year.
Phibro Animal Health Corporation Declares Quarterly Dividend, Payable on June 24, 2015; Appoints George Gunn as Class III Director
May 11 15
On May 11, 2015, Phibro Animal Health Corporation declared quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on June 24, 2015, to stockholders of record at the close of business on June 3, 2015.
The board of directors of the company announced the appointment of Dr. George Gunn as a Class III director of the company, effective immediately. Dr. Gunn will be an independent director. Dr. Gunn's appointment expands the board to 8 directors, 5 of whom are independent directors. Dr. Gunn will also be a member of the company's Compensation Committee. Most recently, Dr. Gunn was the global head of Novartis AG's Animal Health Business Unit from 2004 until 2014 and also served on Novartis's Executive Committee from 2007 to 2014. Dr. Gunn currently serves on the Boards of Directors of two companies that are focused on companion animal health - Animalcare Group plc and Nexvet Biopharma plc.
Phibro Animal Health Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:00 PM
Apr 6 15
Phibro Animal Health Corporation Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 03:00 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Jack Clifford Bendheim, Chairman, Chief Executive Officer, President, Member of Compensation Committee and Member of Retirement Benefits Committee, Richard G. Johnson, Chief Financial Officer, Principal Accounting Officer and Member of Retirement Benefits Committee.
Similar Private Companies By Industry
Recent Private Companies Transactions